EUCTR2019-001461-32-ES进行中（未招募）1 期
Immune Therapy and Analytical Treatment Interruption in HIV+ participants who received an allogeneic stem cell transplantation (ITATI)
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. More than 2 years post-HSCT
- •2. Being off immunosuppression for at least one year (related to allo-HSCT)
- •3. Undetectable levels of HIV replication competent reservoirs in blood (< 0,1 IUPM)
- •4. CD4 count levels higher than 200 cel/mm3.
- •5. Aged at least 18 years and not older than 65 at the day of screening
- •6. Willing to comply with the requirements of the protocol and available for follow-up for the planned duration of the study.
- •7. In the opinion of the principal investigator or designee, the participant has understood the information provided and capable of giving written informed consent.
- •8. If heterosexually active female; using an effective method of contraception (hormonal contraception, intra-uterine device (IUD), or anatomical sterility in self or partner1) from 14 days prior to the first bNAbs administration until at least 6 months after the last bNAbs administration; all female volunteers must be willing to undergo urine pregnancy tests at time points specified.
- •9. If heterosexually active male; willing to use an effective method of contraception (anatomical sterility in self) or agree on the use of an effective method of contraception by his partner (hormonal contraception, intra-uterine device (IUD), or anatomical sterility1) from the day of the first bNAbs administration until 6 months after the last bNAbs administration.
- •10. Willing to accept blood draws at time points specified.
- •11. Not sharing injection drug equipment, such as needles.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 5
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Pregnancy or lactating
- •2. Participation in another clinical trial within 12 weeks of study entry (at screening period).
- •3. History or clinical manifestations of any physical or psychiatric disorder which could impair the subject’s ability to complete the study.
研究者
相似试验
招募中
1 期
Maintaining or Stopping immunosuppressive Therapy in patients with ANCA vasculitis and End-stage Renal disease: a prospective, multicenter, randomized, open-label, clinical trialANCA vasculitis, End-stage Renal diseaseCTIS2024-512470-10-00Centre Hospitalier Departemental Vendee136
招募中
4 期
Maintaining or Stopping immunosuppressive Therapy in patients with ANCA vasculitis and End-stage Renal disease: a prospective, multicenter, randomized, open-label, clinical trial2024-512470-10-00Centre Hospitalier Departemental Vendee136
已完成
不适用
COntinuation Versus Interruption of Immunomodulating Drugs in case of an Infectious disease in immune mediated inflammatory disease (IMID) patients, with special attention for COVID-19Immune mediated inflammatory diseasesautoimmune diseases100179691000381610023213NL-OMON54899Sint Maartenskliniek2,200
已完成
4 期
COntinuation Versus Interruption of Immunomodulating Drugs in case of an Infectious disease in IMID patients (COVID I2 study), with special attention for COVID 19: a pragmatic, explorative randomized controlled trial<p>Rheumatoid arthritis<br />Psoriatic arthritis<br />Axial spondyloarthritis<br />Immune mediated inflammatory diseases<br />Inflammatory rheumatic diseases</p>10003816NL-OMON22848Sint Maartenskliniek2,200
进行中（未招募）
不适用
INDUCTION TREATMENT FOLLOWED BY IMMUNOSUPPRESSION WITHDRAWAL IN LIVER TRANSPLANTATION: A COMPARATIVE TRIAL.Tratamiento de inducción y retirada de la inmunosupresión en el trasplante hepático. Estudio comparativo - ATEGE_LIVERiver transplantationEUCTR2005-005635-10-ESiver Unit, ICMD, Hospital Clinic Barcelona